Phase II Study of Dose-Adjusted EPOCH+/-Rituximab in Adults With Untreated Burkitt Lymphoma, c-MYC Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Apr 2018
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Filgrastim; Prednisone; Vincristine
- Indications Burkitt's lymphoma; Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 17 May 2017 Status changed from recruiting to active, no longer recruiting.
- 02 Mar 2017 Planned End Date changed from 28 Feb 2021 to 28 Feb 2023.
- 02 Mar 2017 Planned primary completion date changed from 31 Dec 2018 to 28 Feb 2021.